AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27177789 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Federica Ferrarini und 21 weiteren Autor:innen. Beteiligte Einrichtung: Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy. Hauptthemen laut MEDLINE: Glioblastoma, AMP-Activated Protein Kinases, Biomarkers, Tumor, Brain Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union.
Abstract (Originalsprache)
Phosphorylated ACC (pACC), a downstream effector of the LKB1/AMPK pathway, may support tumor bioenergetics and exert a tumor-promoting role in glioblastoma (GBM). In the randomized REGOMA trial, pACC expression was associated with improved overall survival (OS) in GBM patients treated with regorafenib, but its validity in large cohorts is unclear. This study aimed to characterize pACC and phosphorylated AMPK (pAMPK) expression in a real-world GBM cohort and to assess their prognostic and predictive value in patients receiving second-line regorafenib or fotemustine/lomustine. In this retrospective, multicenter translational study, pACC and pAMPK were assessed by immunohistochemistry on FFPE tumor sections from 174 IDH-wild-type GBM patients treated with regorafenib (n = 84) or fotemustine/lomustine (n = 90). Staining was performed with a validated anti-pACC monoclonal antibody and quantified by digital pathology. Survival analyses included univariable and multivariable Cox proportional hazards models, with interaction testing. pACC and pAMPK were expressed in 85.6% and 95.4% of samples, respectively, with heterogeneous spatial patterns. Neither marker was significantly associated with OS in the univariable analyses, and neither retained independent prognostic value in multivariable analysis. Regorafenib was associated with significantly longer OS than alkylating agents (10.4 vs. 6.3 months; p = 0.0021). However, the treatment-by-pACC interaction test was not statistically significant (adjusted p = 0.610), providing no formal evidence of a differential treatment effect by pACC status. Although pACC-positive expression was enriched among patients experiencing longer overall survival under regorafenib, formal treatment-by-biomarker interaction was non-significant. These exploratory findings indicate that pACC is not an established predictive biomarker and warrant prospectively powered evaluation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Basic and Translational Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
- Clinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
- Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, 35128 Padua, Italy.
- UOC Radioterapia Oncologica, Ente Ecclesiastico Ospedale F Miulli, 70021 Acquaviva delle Fonti (BA), Italy.
- Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, 47014 Meldola (FC), Italy.
- Surgical Pathology and Cytopathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, 35128 Padua, Italy.
ORCID-Profile: Federica Ferrarini, Paola Del Bianco, Tiziana Talienti, Matteo Mauceri, Daniele Boso, Martina Bedeschi, Mario Caccese, Marta Padovan, Isacco Desideri, Enrico Franceschi, Michela Buglione di Monale E Bastia, Gian Luca De Salvo, Alba Fiorentino, Anna Tesei, Tommaso Mazza, Giuseppe Lombardi, Stefano Indraccolo
Förderung
- European Union
Zitieren
APA
Ferrarini, F., Del Bianco, P., Corrà, M., Talienti, T., Mauceri, M., Boso, D., Romanazzi, G., Bedeschi, M., Caccese, M., Padovan, M., Guerriero, A., Esposito, G., Desideri, I., Franceschi, E., Gaviani, P., Buglione di Monale E Bastia, M., De Salvo, G. L., Fiorentino, A., Tesei, A., …, & Indraccolo, S. (2026). AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27177789
Vancouver
Ferrarini F, Del Bianco P, Corrà M, Talienti T, Mauceri M, Boso D, et al. AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27177789
BibTeX
@article{Ferrarini2026,
author = {Ferrarini, Federica and Del Bianco, Paola and Corrà, Martina and Talienti, Tiziana and Mauceri, Matteo and Boso, Daniele and Romanazzi, Giusi and Bedeschi, Martina and Caccese, Mario and Padovan, Marta and Guerriero, Angela and Esposito, Giovanni and Desideri, Isacco and Franceschi, Enrico and Gaviani, Paola and Buglione di Monale E Bastia, Michela and De Salvo, Gian Luca and Fiorentino, Alba and Tesei, Anna and Mazza, Tommaso and Lombardi, Giuseppe and Indraccolo, Stefano},
title = {AMPK Pathway Activation Markers in GBM: Expression Patterns and Clinical Associations in a Real-World Study},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27177789}
}
EUVIMED